Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $6.4 million.

  • Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) rose 27.08% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 28.68%. This contributed to the annual value of $23.9 million for FY2025, which is 28.68% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Depreciation & Amortization (CF) of $6.4 million as of Q3 2025, which was up 2.62% from $6.2 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $6.4 million for Q3 2025, and its period low was $1.9 million during Q1 2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $4.8 million, with a median of $4.8 million in 2024.
  • Data for Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY spiked of 69.54% (in 2024) over the last 5 years.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $2.6 million in 2021, then grew by 4.51% to $2.7 million in 2022, then soared by 58.53% to $4.3 million in 2023, then grew by 22.80% to $5.2 million in 2024, then rose by 27.08% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $6.2 million for Q2 2025, and $6.1 million during Q1 2025.